AR084401A1 - COMBINACION DEL COMPUESTO GlyT1 CON ANTIPSICOTICOS - Google Patents
COMBINACION DEL COMPUESTO GlyT1 CON ANTIPSICOTICOSInfo
- Publication number
- AR084401A1 AR084401A1 ARP110102840A ARP110102840A AR084401A1 AR 084401 A1 AR084401 A1 AR 084401A1 AR P110102840 A ARP110102840 A AR P110102840A AR P110102840 A ARP110102840 A AR P110102840A AR 084401 A1 AR084401 A1 AR 084401A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- glyt1
- substituted
- pharmaceutical combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Combinación farmacéutica de un inhibidor del transportador de glicina (GlyT1) y un fármaco antipsicótico atípico que puede utilizarse para el tratamiento de los síntomas positivos y negativos de la esquizofrenia.Reivindicación 1: Combinación farmacéutica que comprende un fármaco antipsicótico atípico y un antagonista de receptor de GlyT1 de fórmula (1) en la que: Ar es un grupo heteroarilo de 6 elementos sustituido que contiene uno, dos o tres átomos de nitrógeno, y en el que los grupos heteroarilo pueden sustituirse con uno o más sustituyentes seleccionados de entre el grupo que consiste de halógeno, alquilo C1-6 o alquilo C1-6 sustituido con halógeno; R1 es hidrógeno o alquilo C1-6; R2 es alquilo C1-6 sustituido con halógeno; R3, R4 y R6 son, independientemente entre sí, hidrógeno, halógeno, alquilo C1-6 o alcoxi C1-6; R5 es SO2R10; R10 es alquilo C1-6 sustituido opcionalmente con halógeno; o sales de adición de ácido farmacéuticamente aceptables de los mismos, así como formas enantioméricas de los mismos. Reivindicación 3: Combinación farmacéutica según la reivindicación 2, que comprende un fármaco antipsicótico atípico, seleccionado de entre el grupo que consiste de risperidona, paliperidona, olanzapina, aripiprazol, quetiapina o ziprasidona y el antagonista de receptor de GlyT1 [4-(3-fluoro-5-trifluorometil-piridin-2-il)-piperazín-1-il]-[5-metanosulfonil-2-(2,2,2-trifluoro-1-metiletoxi)-fenil]-metanona. Reivindicación 4: Combinación farmacéutica que comprende un fármaco antipsicótico atípico seleccionado de entre el grupo que consiste de olanzapina o risperidona y un antagonista de receptor de GlyT1 que es de formula (2) o sales de adición de ácido farmacéuticamente aceptables de los mismos, así como formas enantioméricas de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10172316 | 2010-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR084401A1 true AR084401A1 (es) | 2013-05-15 |
Family
ID=44512856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102840A AR084401A1 (es) | 2010-08-09 | 2011-08-05 | COMBINACION DEL COMPUESTO GlyT1 CON ANTIPSICOTICOS |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20120035156A1 (es) |
| EP (1) | EP2603219B1 (es) |
| JP (1) | JP2013533297A (es) |
| KR (1) | KR101455947B1 (es) |
| CN (1) | CN103068388A (es) |
| AR (1) | AR084401A1 (es) |
| AU (1) | AU2011288536B2 (es) |
| BR (1) | BR112013003068A2 (es) |
| CA (1) | CA2803656A1 (es) |
| CL (1) | CL2013000378A1 (es) |
| CR (1) | CR20130027A (es) |
| CY (1) | CY1115886T1 (es) |
| DK (1) | DK2603219T3 (es) |
| EA (1) | EA201291477A1 (es) |
| EC (1) | ECSP13012431A (es) |
| ES (1) | ES2521596T3 (es) |
| HR (1) | HRP20141199T1 (es) |
| MA (1) | MA34457B1 (es) |
| MX (1) | MX2013001166A (es) |
| NZ (1) | NZ604891A (es) |
| PE (1) | PE20131100A1 (es) |
| PL (1) | PL2603219T3 (es) |
| PT (1) | PT2603219E (es) |
| SG (1) | SG187108A1 (es) |
| SI (1) | SI2603219T1 (es) |
| TW (1) | TW201211019A (es) |
| WO (1) | WO2012019970A1 (es) |
| ZA (1) | ZA201300434B (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2764702C2 (ru) * | 2014-10-07 | 2022-01-19 | Сейдж Терапьютикс, Инк. | Нейроактивные соединения и способы их применения |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2753632T3 (da) | 2011-09-08 | 2023-07-10 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelse heraf |
| ES2886506T3 (es) | 2013-03-13 | 2021-12-20 | Sage Therapeutics Inc | Esteroides neuroactivos |
| EP3076953A1 (en) * | 2013-12-03 | 2016-10-12 | F. Hoffmann-La Roche AG | Pharmaceutical composition |
| US9868975B2 (en) * | 2014-04-30 | 2018-01-16 | Yufeng Jane Tseng | Use of known compounds as D-amino acid oxidase inhibitors |
| WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| JP6882996B2 (ja) | 2015-07-06 | 2021-06-02 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびそれらの使用の方法 |
| AU2016289967B2 (en) | 2015-07-06 | 2021-09-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| HUE055199T2 (hu) | 2015-07-06 | 2021-11-29 | Sage Therapeutics Inc | Oxiszterolok és alkalmazási eljárásaik |
| SI3436022T1 (sl) | 2016-04-01 | 2022-08-31 | Sage Therapeutics, Inc. | Oksisteroli in postopki za uporabo le-teh |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| MA45598B1 (fr) | 2016-07-07 | 2021-09-30 | Sage Therapeutics Inc | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda |
| CA3038900A1 (en) | 2016-09-30 | 2018-04-05 | Sage Therapeutics, Inc. | C7 substituted oxysterols and methods as nmda modulators |
| TWI815800B (zh) | 2016-10-18 | 2023-09-21 | 美商賽吉醫療公司 | 氧固醇(oxysterol)及其使用方法 |
| EP3529256B1 (en) | 2016-10-18 | 2023-08-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CN107469087A (zh) * | 2017-09-10 | 2017-12-15 | 孙永丽 | 用于治疗精神病的制剂 |
| MX2020004975A (es) * | 2017-11-14 | 2020-08-24 | Sk Biopharmaceuticals Co Ltd | Mezcla que contiene compuesto de carbamato para prevencion, mitigacion o tratamiento de esquizofrenia. |
| CA3166938A1 (en) | 2020-01-09 | 2021-07-15 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100774622B1 (ko) | 2003-08-11 | 2007-11-08 | 에프. 호프만-라 로슈 아게 | Ｏｒ-치환된 페닐 그룹을 갖는 피페라진 및 ｇｌｙｔ1억제제로서 그의 용도 |
| WO2006000222A2 (en) * | 2004-06-24 | 2006-01-05 | H. Lundbeck A/S | The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia |
| CA2603939C (en) * | 2005-04-08 | 2013-08-27 | Pfizer Products Inc. | Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors |
| GB0612420D0 (en) * | 2006-06-22 | 2006-08-02 | Glaxo Group Ltd | Compounds |
| UA94615C2 (uk) * | 2006-06-28 | 2011-05-25 | Амген Інк. | Інгібітори транспортера-1 гліцину |
-
2011
- 2011-08-01 US US13/195,045 patent/US20120035156A1/en not_active Abandoned
- 2011-08-05 CN CN2011800387771A patent/CN103068388A/zh active Pending
- 2011-08-05 BR BR112013003068A patent/BR112013003068A2/pt not_active IP Right Cessation
- 2011-08-05 PL PL11739097T patent/PL2603219T3/pl unknown
- 2011-08-05 DK DK11739097.1T patent/DK2603219T3/da active
- 2011-08-05 WO PCT/EP2011/063533 patent/WO2012019970A1/en active Application Filing
- 2011-08-05 MA MA35645A patent/MA34457B1/fr unknown
- 2011-08-05 PT PT117390971T patent/PT2603219E/pt unknown
- 2011-08-05 EA EA201291477A patent/EA201291477A1/ru unknown
- 2011-08-05 KR KR1020137005858A patent/KR101455947B1/ko not_active IP Right Cessation
- 2011-08-05 SI SI201130310T patent/SI2603219T1/sl unknown
- 2011-08-05 JP JP2013523575A patent/JP2013533297A/ja active Pending
- 2011-08-05 AU AU2011288536A patent/AU2011288536B2/en not_active Ceased
- 2011-08-05 EP EP11739097.1A patent/EP2603219B1/en not_active Not-in-force
- 2011-08-05 SG SG2013003678A patent/SG187108A1/en unknown
- 2011-08-05 ES ES11739097.1T patent/ES2521596T3/es active Active
- 2011-08-05 CA CA2803656A patent/CA2803656A1/en not_active Abandoned
- 2011-08-05 AR ARP110102840A patent/AR084401A1/es unknown
- 2011-08-05 MX MX2013001166A patent/MX2013001166A/es not_active Application Discontinuation
- 2011-08-05 PE PE2013000235A patent/PE20131100A1/es not_active Application Discontinuation
- 2011-08-05 NZ NZ604891A patent/NZ604891A/en not_active IP Right Cessation
- 2011-08-08 TW TW100128250A patent/TW201211019A/zh unknown
-
2013
- 2013-01-16 ZA ZA2013/00434A patent/ZA201300434B/en unknown
- 2013-01-22 CR CR20130027A patent/CR20130027A/es unknown
- 2013-02-07 CL CL2013000378A patent/CL2013000378A1/es unknown
- 2013-02-07 EC ECSP13012431 patent/ECSP13012431A/es unknown
-
2014
- 2014-11-14 CY CY20141100952T patent/CY1115886T1/el unknown
- 2014-12-11 HR HRP20141199AT patent/HRP20141199T1/hr unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2764702C2 (ru) * | 2014-10-07 | 2022-01-19 | Сейдж Терапьютикс, Инк. | Нейроактивные соединения и способы их применения |
Also Published As
| Publication number | Publication date |
|---|---|
| CL2013000378A1 (es) | 2013-05-03 |
| PL2603219T3 (pl) | 2015-03-31 |
| CN103068388A (zh) | 2013-04-24 |
| AU2011288536B2 (en) | 2014-10-09 |
| ZA201300434B (en) | 2013-09-25 |
| EP2603219B1 (en) | 2014-09-17 |
| TW201211019A (en) | 2012-03-16 |
| CY1115886T1 (el) | 2017-01-25 |
| ECSP13012431A (es) | 2013-03-28 |
| KR20130045379A (ko) | 2013-05-03 |
| WO2012019970A1 (en) | 2012-02-16 |
| SI2603219T1 (sl) | 2014-12-31 |
| ES2521596T3 (es) | 2014-11-13 |
| US20120035156A1 (en) | 2012-02-09 |
| AU2011288536A1 (en) | 2013-01-31 |
| EP2603219A1 (en) | 2013-06-19 |
| MX2013001166A (es) | 2013-03-22 |
| EA201291477A1 (ru) | 2013-06-28 |
| DK2603219T3 (da) | 2014-10-13 |
| SG187108A1 (en) | 2013-02-28 |
| KR101455947B1 (ko) | 2014-10-28 |
| PE20131100A1 (es) | 2013-09-23 |
| NZ604891A (en) | 2015-01-30 |
| PT2603219E (pt) | 2014-11-25 |
| MA34457B1 (fr) | 2013-08-01 |
| BR112013003068A2 (pt) | 2016-06-28 |
| CA2803656A1 (en) | 2012-02-16 |
| HRP20141199T1 (hr) | 2015-02-13 |
| JP2013533297A (ja) | 2013-08-22 |
| CR20130027A (es) | 2013-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR084401A1 (es) | COMBINACION DEL COMPUESTO GlyT1 CON ANTIPSICOTICOS | |
| PE20160540A1 (es) | Inhibidores de bromodominios | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| PE20130382A1 (es) | Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a | |
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| TW200738655A (en) | Novel bicyclic sulfonamide derivatives | |
| EA201491671A1 (ru) | Гетероциклильные соединения | |
| MX2012007536A (es) | Derivados de heteroarilo que contienen nitrogeno. | |
| PE20160839A1 (es) | Derivados de 4-azaindol | |
| EA201391239A1 (ru) | Пирроло[2,3-d]пиримидиновые производные в качестве ингибиторов тропомиозин-связанных киназ | |
| PE20140970A1 (es) | Derivados de 6-ciclobutil-1,5-dihidro-pirazol [3,4-d) pirimidin-4-ona y su uso como inhibidores de pde9a | |
| MD20140084A2 (en) | New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same | |
| PE20141380A1 (es) | Imidazopiridazinas como inhibidores de quinasa akt | |
| AR085316A1 (es) | Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas | |
| AR082799A1 (es) | Derivados de quinolina y quinoxalina como inhibidores de quinasa | |
| PE20141308A1 (es) | Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a | |
| CR10784A (es) | Nuevos derivados de aminopirimidina como inhibidores de plki | |
| AR081072A1 (es) | Derivados de 3,3-dimetil-tetrahidroquinolina, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento de la diabetes, obesidad y dislipemia | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| PE20121438A1 (es) | Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a | |
| ATE507212T1 (de) | Morpholine als 5ht2c-agonisten | |
| AR072962A1 (es) | Derivados de pirimidin-4-ona sustituidos | |
| IN2012DN03337A (es) | ||
| PE20141352A1 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
| PE20160934A1 (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolisis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |